Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 17, 2020

View Archived Issues

Angiopoietin trouble can lead to lymphedema

Prelude Therapeutics initiates phase I study of PRT-1419

Enrollment initiates in first-in-human study of ONC-206

New company Cullinan Florentine to develop bispecific antibody CLN-049 for AML

Phase I data for coadministered hookworm vaccine candidates, Na-GST-1 and Na-APR-1

PZ-1818, a dual-acting 5-HT6 receptor inverse agonist/MAO-B inhibitor

Arrowhead presents interim phase II data for ARO-AAT in AATD-associated liver disease

Interim results from ongoing phase Ib/II study of cavrotolimod

AstraZeneca discloses KRAS mutant inhibitors

Chaluesheng Medical Technology divulges RET inhibitors

Chinese researchers present exportin-1 receptor antagonists

New target identified for ZIKV-induced microcephaly

Ferro Therapeutics patents new GPX4 inhibitors

University of California discovers 5-HT2A receptor modulators

First patient dosed in phase II study of GC-4419 for COVID-19

New rat model of cortical demyelination reveals benefit of anti-CD20 antibody therapy

Enrollment ongoing in phase I study of INV-101

TFF reports topline safety data from phase I study of voriconazole inhalation powder

DoD grant to support Histogen's evaluation of HST-003 for regeneration of knee cartilage

INmune receives grant to support phase II testing of XPro-1595 in treatment-resistant depression

PARP1 inhibitor AG-014699 confers neuroprotection in experimental PD

AVM receives FDA clearance to study AVM-0703 for COVID-19- and influenza-related ARDS

Tiziana set to study nasally administered foralumab for treatment of COVID-19

Immune-Onc begins first-in-human study of IO-202 for AML and CMML

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...